IT
CPRX icon

Independence Trust’s Catalyst Pharmaceutical CPRX Stock Holding History

Independence Trust’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-42,000
Closed -$103K – 53
2015
Q4 		$103K Buy
42,000
+14,000
+50% +$40.1K 0.13% 66
2015
Q3 		$84K Buy
+28,000
New +$121K 0.09% 99

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Independence Trust's CPRX Position: Q1 2016 in Review

Independence Trust sold out of Catalyst Pharmaceutical (CPRX) in Q1 2016, closing a stake of 42,000 shares — an estimated $103K sold.

Independence Trust first reported a position in CPRX in Q3 2015 and held it in 2 quarters. The position peaked at $103K in Q4 2015. 73 funds tracked by Wall St. Rank hold CPRX as of Q1 2016.

  • Independence Trust reported no remaining Catalyst Pharmaceutical position as of Q1 2016 after selling out during the quarter.
  • Independence Trust sold 42,000 Catalyst Pharmaceutical shares in Q1 2016, an estimated $103K.
  • Independence Trust first reported a position in Catalyst Pharmaceutical in Q3 2015 and held it in 2 quarters.
  • Independence Trust's Catalyst Pharmaceutical position peaked at $103K in Q4 2015.
  • 73 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2016.

Based on Independence Trust's 13F filing for Q1 2016, filed 19 Apr 2016.